Utime Ltd Stock Price, News & Analysis

UTime Limited (NASDAQ: UTME) has received a notification from Nasdaq on August 15, 2025, indicating non-compliance with the minimum stockholders' equity requirement. The company's stockholders' equity has fallen below the required $2.5 million threshold for continued listing on the Nasdaq Capital Market.

The company has been given 45 calendar days until September 29, 2025, to submit a compliance plan. If accepted by Nasdaq, UTime could receive up to 180 calendar days extension to regain compliance. The notification does not immediately affect UTME's listing status on Nasdaq.

UTime (Nasdaq: WTO) has announced a 1-for-10 reverse share split of its Class A ordinary shares, effective March 31, 2025. The move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.

Key details of the reverse split include:

• Outstanding shares will reduce from approximately 36 million to 3.6 million
• New par value will be $0.001 per share
• Trading continues under symbol 'WTO' with new CUSIP number G9411M124
• Fractional shares will be rounded up to the nearest whole number

The split will also affect ordinary shares issuable under outstanding derivative securities and equity incentive plans. VStock Transfer, will serve as the exchange agent, with shareholders holding book-entry or brokerage accounts requiring no action.

UTime (Nasdaq: WTO) announced receiving a notification letter from Nasdaq on October 10, 2024, regarding its failure to meet the minimum bid price requirement. The company's ordinary shares have been below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). UTime has until April 8, 2025, to regain compliance by maintaining a closing bid price of at least $1 for a minimum of 10 consecutive business days.

If UTime fails to meet this requirement within the initial 180-day period, it may be eligible for an additional 180 calendar days, provided it meets other continued listing requirements and submits a written notice of intention to cure the deficiency. The notification has no immediate effect on UTime's Nasdaq listing.

UTime (Nasdaq: WTO), a mobile device manufacturer, has announced a $5 million registered direct offering of its ordinary shares. The company has agreed to sell 7,692,308 ordinary shares at a purchase price of $0.65 per share to certain accredited investors. The offering is expected to close around September 16, 2024, subject to customary closing conditions. The shares are being offered pursuant to a shelf registration statement on Form F-3 filed with the SEC. UTime aims to provide cost-effective products and solutions to consumers globally, particularly focusing on low-income individuals in established and emerging markets.

UTime (Nasdaq: WTO) has announced a 1-for-25 reverse share split, effective September 11, 2024. This move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per ordinary share. Key points include:

• Trading on a split-adjusted basis begins September 11, 2024
• New CUSIP number: G9411M116
• Outstanding shares will reduce from ~450 million to ~18 million
• No fractional shares will be issued; all fractional interests rounded up
• Adjustments will be made to outstanding derivative securities and equity incentive plans

VStock Transfer, is acting as the exchange agent. Shareholders with book-entry or brokerage accounts need not take action, while those with certificates will receive instructions for the exchange process.

UTime (NASDAQ: WTO) has initiated comprehensive financial and legal due diligence on Bowen Therapeutics Inc, marking a significant step in its planned acquisition. This move aligns with UTime's strategy to expand its presence in the innovative medical products sector and strengthen its market position. Bowen Therapeutics, known for its research and development capabilities, particularly in monkeypox vaccine development, is expected to become a key part of UTime's expansion strategy.

The due diligence process will cover various aspects of Bowen Therapeutics' business, including financial statements, assets, liabilities, cash flow, tax records, corporate governance, contracts, intellectual property rights, and potential legal risks. This thorough examination will provide UTime with a comprehensive understanding of Bowen Therapeutics, enabling informed decision-making aligned with its long-term growth strategy in the global healthcare sector.

UTime (NASDAQ: WTO) has signed a non-disclosure agreement (NDA) to acquire Bowen Therapeutics Inc's laboratory at UMASS Medical School, marking its expansion into the global vaccine market. The acquisition aims to support the FDA registration of a monkeypox vaccine developed by Bowen Therapeutics. This strategic move responds to the growing global need for effective monkeypox prevention amid recent outbreaks.

Bowen Therapeutics has developed a novel hexavalent recombinant protein vaccine designed to increase virus-neutralizing antibodies and enhance protection against monkeypox. UTime will take over the laboratory, manage ongoing clinical trials, and lead future vaccine development programs. The transaction is subject to regulatory approvals and is expected to complete within a few months, though there is no guarantee of completion.

UTime (NASDAQ: WTO) has announced its collaboration on Circul VS, a continuous blood pressure measurement technology system developed with Dr. Ehud Baron. The system includes a BPwatch, Ring, and Smart Cradle, integrated into a cloud-based network. Circul VS utilizes ultrasound sensing technology and intelligent algorithms to provide real-time blood pressure waveform data with high accuracy.

The system has undergone clinical trials in partner hospitals, receiving positive feedback for its performance in non-invasive monitoring. Circul VS is designed for various applications, including hypertension screening, long-term management, and acute monitoring in hospital settings. UTime and Dr. Baron plan to further refine the technology for use in ICUs and other medical environments.

UTime (NASDAQ: WTO) has announced plans to participate in several international medical fairs and conferences. The company will showcase its latest medical devices and solutions at MEDICA in Düsseldorf, Germany, one of the world's most influential medical trade fairs. UTime will exhibit innovations in medical monitoring devices and smart diagnostic tools.

Additionally, UTime plans to attend the Cardiology Society Conference, Sleep Conference, and Hypertension Conference in the United States. These events will provide opportunities to present technological advancements and learn from global peers. The company aims to explore potential collaborations with international healthcare organizations and research institutes, focusing on telemedicine and AI applications in healthcare. These initiatives demonstrate UTime's commitment to influencing the global medical landscape and enhancing human health through innovation.